Every round on record, with the sources behind each and the investors on them.
SuperMush sells functional mushroom-based gummies designed for daily health and performance.
supermush.comLinkedInUSFounded 202124 people
8 sources · checked 2 times, last 1h ago
Sources use both “USD 3 million” and “$3 million”; the specific funding article's “$3 million” is used.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $3M | 2026-10-06 | NDude Labs | 8 outlets. #17 in Trending |
8 sources · checked 2 times, last 1h ago [ VERIFIED ] read against 4 of 8 sources Sources use both “USD 3 million” and “$3 million”; the specific funding article's “$3 million” is used. | ||||
SuperMush makes science-backed functional gummies and other supplements for people who want daily support for energy, focus, sleep, passion, and performance.
SuperMush is betting that nootropics, adaptogens, and functional mushrooms can make daily wellness more portable, tasty, and appealing to Gen Z/Y than traditional powders and tinctures, while addressing the fatigue and mental-wellness concerns described in its materials. The $3 million Series A is intended to expand products and formulations and strengthen the team and infrastructure as the brand grows to more than 2,000 US stores, including more than 1,000 Target locations, alongside its website and Amazon sales.
Checked against 10 sources today
Via Alexandria from FullEnrich: type, industry
Also named as backers in company research: Vibrant VC, Humans VC, Mystic VC, Jarret Christie, Ba Minuzzi, Akash Nigam, Jody Levy, Gerard Adams, Julie Smolyansky, Tara Tersigni, Dr. Christian Gonzalez, Devon Levesque, Steven Vigilante, Ryan Lewendon, Andrew Merinoff, Jess Holtz, Braxton Berrios, Connor Saeli, Jeffrey Perlman, Gunnar Lovelace, Jordan Brown, Brendan Brazier, Auston Matthews, Max Lugavere, Marc Randolph, Anthony Gustin, Oliver Trevena, Adrien Grenier